Prescription medicines: how to differentiate information from advertising in the EU
This article was originally published in SRA
Manuel Campolini examines the current state of play on distinguishing between advertising and providing information on prescription medicines in the EU.
You may also be interested in...
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.
Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.